<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Sari Prabandari Prasetyaningrum</style></author><author><style face="normal" font="default" size="100%">Munawaroh Fitriah</style></author><author><style face="normal" font="default" size="100%">Aryati</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of Covid-19 Neutralizing Antibody Levels Post Vaccination using Ichroma™ and iFlash Covid-19 Nab</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ichroma</style></keyword><keyword><style  face="normal" font="default" size="100%">iFlash.</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutralizing Antibody</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">171-174</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. &lt;strong&gt;Methods:&lt;/strong&gt; This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. &lt;strong&gt;Results: &lt;/strong&gt;The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). McNemar's test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland–Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002).&lt;strong&gt; Conclusion:&lt;/strong&gt; Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">171</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Hartono Kahar&lt;sup&gt;1,*&lt;/sup&gt;, Sari Prabandari Prasetyaningrum&lt;sup&gt;2&lt;/sup&gt;, Munawaroh Fitriah&lt;sup&gt;2&lt;/sup&gt;, Aryati&lt;sup&gt;2&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory Instalation, Dr. Soetomo Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Clinical Pathology Specialization Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>